Evidence map›Paper›PMID 30236381›Full record

Observational studyThe Lancet. Child & adolescent health2018

Trajectories of changes in glucose tolerance in a multiethnic cohort of obese youths: an observational prospective analysis.

Alfonso Galderisi, Cosimo Giannini, Ram Weiss, Grace Kim, Veronika Shabanova, Nicola Santoro, Bridget Pierpont, Mary Savoye, Sonia Caprio

3 registry-linked trialsOpen access · bronzeAbstract readObservational Study
In one paragraph

Observational study in The Lancet. Child & adolescent health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05121844 naactive not recruitingnot on this mapstarted 2021, after this paper: background citation

Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform: Comprehensive Weight Optimization Program and Customized Lifestyle Modifications

TypeinterventionalSponsorSignos IncRan2021 to 2027Enrolled31,187ConditionsWeight Loss, Metabolic Syndrome, Pre-diabetes, Central ObesityArmsContinuous Glucose Monitor Device
NCT05874635 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

Use of Signos mHealth Platform in Participants With Non-Insulin Dependent Type 2 Diabetes: Weight and Blood Glucose

TypeinterventionalSponsorSignos IncRan2023 to 2029Enrolled20,000ConditionsWeight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central ObesityArmsContinuous Glucose Monitor Device
NCT06214221 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

A Randomized Controlled Trial Evaluating the Safety and Effectiveness of the Intelligently-Driven Signos System for Personalized Weight Management in Overweight and Obese Adults

TypeinterventionalSponsorSignos IncRan2024 to 2026Enrolled380ConditionsOverweight and Obesity, Metabolic Syndrome, Weight LossArmsSignos System, Standard Lifestyle Education
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Review
  3. Prediabetes in children and adolescents: what do we need to know?Annals of pediatric endocrinology & metabolism · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Prediabetes in children and adolescents: An updated review.World journal of clinical pediatrics · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Alfonso GalderisiDepartment of Pediatrics, Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT, USA; Department of Women and Children's Health, University of Padova, Padua, Italy.
Cosimo GianniniDepartment of Pediatrics, Ospedale "SS Annunziata", Chieti, Italy.
Ram WeissDepartment of Pediatrics, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel.
Grace KimSeattle Children's Hospital, Seattle, WA, USA.
Veronika ShabanovaDepartment of Pediatrics, Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Nicola SantoroDepartment of Pediatrics, Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Bridget PierpontDepartment of Pediatrics, Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Mary SavoyeDepartment of Pediatrics, Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Sonia CaprioDepartment of Pediatrics, Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT, USA. Electronic address: sonia.caprio@yale.edu.
Yale University · USOspedale SS. Annunziata · ITRambam Health Care Campus · ILSeattle Children's Hospital · US

Funding

METABOLIC PREDICTORS AND MARKERS OF CHILDHOOD OBESITYR01HD028016 · NICHD · YALE UNIVERSITY · PI CAPRIO, SONIA · 1991 to 2024
$8.9M
Pathogenesis of youth onset pre-diabetes and Type 2 diabetesR01DK111038 · NIDDK · YALE UNIVERSITY · PI CAPRIO, SONIA · 2016 to 2025
$7.0M
Study to Investigate the Pathophysiology of Type 2 Diabetes in YouthR01HD040787 · NICHD · YALE UNIVERSITY · PI CAPRIO, SONIA · 2000 to 2014
$5.6M
Mechanisms of Obesity and Its Metabolic Complications in Youth.R01DK114504 · NIDDK · YALE UNIVERSITY · PI SANTORO, NICOLA · 2018 to 2022
$1.9M
PATHOPHYSIOLOGY OF METABOLIC DEFECTS OF JUVENILE OBESITYK24HD001464 · NICHD · YALE UNIVERSITY · PI CAPRIO, SONIA · 2001 to 2010
$1.4M
NICHD NIH HHS K24 HD001464NICHD NIH HHS R01 HD028016NICHD NIH HHS R01 HD040787NIDDK NIH HHS R01 DK111038NIDDK NIH HHS R01 DK114504
6 · The paper itself

Abstract

backgroundType 2 diabetes is preceded by a prediabetic stage of impaired glucose tolerance that affects 10-23% of youth and is expected to double over the next decade. The natural history of impaired glucose tolerance and the determinants of β-cell dynamic response have never been investigated longitudinally in young people. We aimed to investigate the clinical and metabolic determinants of longitudinal glucose tolerance changes and β-cell function in a multiethnic cohort of obese youth.

methodsWe followed up prospectively a multiethnic cohort of overweight and obese (body-mass index >85th percentile) adolescents with baseline normal glucose tolerance (plasma glucose <140 mg/dL) or impaired glucose tolerance (plasma glucose 140-199 mg/dL) at the Yale Pediatric Obesity Clinic (CT, USA). All participants underwent a 3-h oral glucose tolerance test at baseline and after 2 years to estimate insulin secretion (oral disposition index) in the context of body insulin sensitivity. As part of standard care at the clinic, all participants received dietary advice and underwent dietary assessment every 5-6 months. No structured lifestyle or pharmacological intervention was administered.

findingsBetween January, 2010, and December, 2016, 526 adolescents (mean age 12·7 years, range 10·6-14·2) were enrolled to our study. At baseline, 364 had normal and 162 had impaired glucose tolerance. Median follow-up was 2·9 years (IQR 2·7-3·1). 105 (65%) of 162 with impaired glucose tolerance at baseline reverted to normal glucose tolerance at follow-up, 44 (27%) had persistent impaired glucose tolerance, and 13 (8%) progressed to type 2 diabetes. A feature of reversion to normal glucose tolerance was a roughly four-fold increase in the oral disposition index (from median 0·94 [IQR 0·68-1·35] at baseline to 3·90 [2·58-6·08] at follow-up; p<0·0001) and a significantly higher oral disposition index at follow-up compared with participants who maintained normal glucose tolerance across the study period (median 3·90 [IQR 2·58-6·08] vs 1·59 [1·12-2·23]; p<0·0001). By contrast, a decrease in insulin secretion was seen in participants who had persistent impaired glucose tolerance (median 1·31 [IQR 1·01-1·85]; p<0·0001) or who progressed to type 2 diabetes (0·20 [0·12-0·58]; p<0·0001), compared with participants who maintained normal glucose tolerance across the study period. Non-Hispanic white ethnic origin conferred five times the odds of reversion to normal glucose tolerance compared with non-Hispanic black ethnic origin (OR 5·06, 95% CI 1·86-13·76; p=0·001), with a two times greater annual increase in the oral disposition index (β 2·32, 95% CI 0·05-4·60; p=0·045).

interpretationImpaired glucose tolerance is highly reversible in obese adolescents. Ethnic origin is the main clinical modifier of the dynamic β-cell response to prediabetic hyperglycaemia and, thus, determines the reversibility of impaired glucose tolerance, or its persistence. Therapeutic interventions for impaired glucose tolerance should target the specific mechanisms underpinning glucose tolerance changes in high-risk ethnic groups.

fundingNational Institutes of Health (National Institute of Child Health and Human Development, National Center for Research Resources, and National Institute of Diabetes and Digestive and Kidney Diseases), American Diabetes Association, International Society for Pediatric and Adolescent Diabetes, Robert Leet Patterson and Clara Guthrie Patterson Trust, European Society for Pediatric Endocrinology, American Heart Association, and the Allen Foundation.

Indexed as

AdolescentChildFemaleGlucose IntoleranceGlucose Tolerance TestHumansLongitudinal StudiesMalePediatric ObesityProspective Studies

Identifiers

PMID30236381
PMCPMC6190831
OpenAlexW2888644421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.